Yes, Forteo Treats Bone Conditions
Forteo (teriparatide) is a prescription medication for specific bone disorders. It contains synthetic parathyroid hormone that stimulates new bone formation by acting on osteoblasts.[1]
What Conditions Does Forteo Treat?
Forteo is FDA-approved to increase bone mass in postmenopausal women with osteoporosis at high risk for fracture, men with primary or hypogonadal osteoporosis at high fracture risk, and people with glucocorticoid-induced osteoporosis at high risk.[1] It's used when other treatments like bisphosphonates fail or aren't suitable, typically for no more than 2 years due to osteosarcoma risk in animal studies.[2]
How Does Forteo Work on Bones?
Injected daily under the skin, Forteo mimics the body's parathyroid hormone to promote bone-building cells while reducing resorption over time. Clinical trials showed it increased lumbar spine bone density by 9-13% after 21 months, outperforming placebo.[3]
Who Can't Use Forteo?
Not for people with Paget's disease, unexplained high bone turnover, prior radiation therapy, bone metastases, hypercalcemia, or children. Avoid in those with skeletal malignancies or hereditary bone disorders.[1]
Common Side Effects and Risks
Dizziness, leg cramps, nausea, and joint pain occur in over 10% of users. Black box warning for potential osteosarcoma risk limits use to 2 years lifetime.[2] Monitor calcium levels; hypercalcemia affects 1-2%.[3]
How Does Forteo Compare to Other Osteoporosis Drugs?
| Drug | Mechanism | Use Case | Key Difference |
|------|-----------|----------|---------------|
| Forteo | Anabolic (builds bone) | High-risk osteoporosis | Daily injection; short-term only |
| Prolia (denosumab) | Antiresorptive (slows breakdown) | Osteoporosis, high fracture risk | Every 6 months injection; longer use |
| Fosamax (alendronate) | Antiresorptive | Postmenopausal osteoporosis | Oral pill; common first-line |
Forteo excels in severe cases needing rapid bone gain but requires refrigeration and self-injection.[4]
Patent and Availability Details
Forteo, made by Eli Lilly, had key U.S. patents expire in 2019-2022, allowing generics like teriparatide pens. Check DrugPatentWatch.com for latest expiry dates, litigation, and biosimilar entries.[5]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021318s042lbl.pdf
[2] NIH Osteoporosis Info: https://www.niams.nih.gov/health-topics/osteoporosis/diagnosis-treatment-and-steps-to-take
[3] NEJM Trial (2001): https://www.nejm.org/doi/full/10.1056/NEJM200111293452204
[4] American College of Rheumatology Guidelines: https://www.rheumatology.org/Portals/0/Files/Osteoporosis-Guidelines.pdf
[5] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/FORTEO